Alkem Laboratories, based in Mumbai, has announced the launch of generic empagliflozin and its combinations in India under the brand name “Empanorm” to treat type-2 diabetes, chronic kidney disease, and heart failure. The medication will be priced approximately 80% lower than the innovator products.
The shares of Alkem Laboratories Limited were trading at ₹4,709 down by ₹68.75 or 1.44% on the NSE at 12.18 pm today. The company is introducing several combination therapies including Empanorm L (empagliflozin and linagliptin), Empanorm Duo, Alsita E (empagliflozin and sitagliptin), and Empanorm M (empagliflozin and metformin).
Alkem’s versions feature an anti-counterfeit security band and include comprehensive patient education materials in multiple languages. The company has also developed a smaller tablet size for patient convenience.
“As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone,” said Dr. Vikas Gupta, Alkem’s CEO. He added that the company plans to leverage its distribution network to improve treatment accessibility nationwide.
Empagliflozin is an SGLT-2 inhibitor that has shown benefits beyond diabetes management, including positive effects on cardiovascular and kidney health.
Alkem, the fifth-largest pharmaceutical company in India, operates 19 manufacturing facilities and various R&D centers across India and the US. The company specializes in anti-infectives, gastrointestinal medications, pain management drugs, and supplements while expanding its chronic therapy offerings.
Published on March 12, 2025.
